Rennie Claire, Morshed Nabila, Faria Matthew, Collins-Praino Lyndsey, Care Andrew
School of Life Sciences, University of Technology Sydney, Sydney 2007, New South Wales, Australia.
Australian Institute for Microbiology and Infection, Sydney 2007, New South Wales, Australia.
Mol Pharm. 2025 Feb 3;22(2):940-957. doi: 10.1021/acs.molpharmaceut.4c01179. Epub 2025 Jan 13.
Neuronanomedicine harnesses nanoparticle technology for the treatment of neurological disorders. An unavoidable consequence of nanoparticle delivery to biological systems is the formation of a protein corona on the nanoparticle surface. Despite the well-established influence of the protein corona on nanoparticle behavior and fate, as well as FDA approval of neuro-targeted nanotherapeutics, the effect of a physiologically relevant protein corona on nanoparticle-brain cell interactions is insufficiently explored. Indeed, less than 1% of protein corona studies have investigated protein coronas formed in cerebrospinal fluid (CSF), the fluid surrounding the brain. Herein, we utilize two clinically relevant polymeric nanoparticles (PLGA and PLGA-PEG) to evaluate the formation of serum and CSF protein coronas. LC-MS analysis revealed distinct protein compositions, with selective enrichment/depletion profiles. Enhanced association of CSF precoated particles with brain cells demonstrates the importance of selecting physiologically relevant biological fluids to more accurately study protein corona formation and subsequent nanoparticle-cell interactions, paving the way for improved nanoparticle engineering for in vivo applications.
神经纳米医学利用纳米颗粒技术治疗神经系统疾病。纳米颗粒递送至生物系统不可避免的结果是在纳米颗粒表面形成蛋白冠。尽管蛋白冠对纳米颗粒行为和命运的影响已得到充分证实,并且美国食品药品监督管理局(FDA)已批准了神经靶向纳米疗法,但生理相关蛋白冠对纳米颗粒与脑细胞相互作用的影响仍未得到充分探索。事实上,不到1%的蛋白冠研究调查了在脑脊液(CSF,即包围大脑的液体)中形成的蛋白冠。在此,我们利用两种临床相关的聚合物纳米颗粒(聚乳酸-羟基乙酸共聚物(PLGA)和聚乳酸-羟基乙酸共聚物-聚乙二醇(PLGA-PEG))来评估血清和脑脊液蛋白冠的形成。液相色谱-质谱(LC-MS)分析揭示了不同的蛋白质组成,具有选择性富集/耗尽特征。脑脊液预包被颗粒与脑细胞的增强结合表明,选择生理相关生物流体对于更准确地研究蛋白冠形成及随后的纳米颗粒-细胞相互作用非常重要,为改进体内应用的纳米颗粒工程铺平了道路。